NCX 466
Biological Activity
Cyclooxygenase (COX)-inhibiting nitric oxide (NO) donor (CINOD). Inhibits COX-1 and COX-2 while releasing NO. Demonstrates higher efficacy than naproxen, its congener drug, in reducing levels of profibrotic cytokine transforming growth factor-β and oxidative stress in a mouse model of bleomycin-induced lung fibrosis. Orally available.
Technical Data
| M. Wt | 436.41 |
| Formula | C20H24N2O9 |
| Storage | Store at -20°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 1262956-64-8 |
| PubChem ID | 49855334 |
| InChI Key | QTUSNUCZIUBIBF-LIRRHRJNSA-N |
| Smiles | O=C(OCCCC[C@H](O[N+]([O-])=O)CO[N+]([O-])=O)[C@@H](C)C2=CC1=CC=C(OC)C=C1C=C2 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Solubility Data
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 43.64 | 100 | |
| ethanol | 43.64 | 100 |
Preparing Stock Solutions
The following data is based on the product molecular weight 436.41. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 2.29 mL | 11.46 mL | 22.91 mL |
| 5 mM | 0.46 mL | 2.29 mL | 4.58 mL |
| 10 mM | 0.23 mL | 1.15 mL | 2.29 mL |
| 50 mM | 0.05 mL | 0.23 mL | 0.46 mL |
Molarity Calculator
Reconstitution Calculator
Dilution Calculator
Product Datasheets
References
References are publications that support the biological activity of the product.
Pini et al (2012) Prevention of bleomycin-induced lung fibrosis in mice by a novel approach of parallel inhibition of cyclooxygenase and nitric-oxide donation using NCX 466, a prototype cyclooxygenase inhibitor and nitric-oxide donor. J.Pharmacol.Exp.Ther. 341 493 PMID: 22344408
If you know of a relevant reference for NCX 466, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: NCX 466, NCX 466 supplier, NCX466, Cyclooxygenases, COX, COX1, COX2, COX-1, COX-2, inhibitors, inhibits, nitric, oxide, NO, donor, CINOD, inflammation, anti-inflammatory, profibrotic, Donors, /, Precursors, Cyclooxygenase, 4537, Tocris Bioscience
Citations for NCX 466
Citations are publications that use Tocris products.
Currently there are no citations for NCX 466. Do you know of a great paper that uses NCX 466 from Tocris? Please let us know.
Reviews for NCX 466
There are currently no reviews for this product. Be the first to review NCX 466 and earn rewards!
Have you used NCX 466?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Cancer Research Product Guide
A collection of over 750 products for cancer research, the guide includes research tools for the study of:
- Cancer Metabolism
- Epigenetics in Cancer
- Receptor Signaling
- Cell Cycle and DNA Damage Repair
- Angiogenesis
- Invasion and Metastasis
Immunology Product Listing
A collection of over 190 products for immunology research, the guide includes research tools for the study of:
- Chemokine and Cytokine Signaling
- Chemotaxis
- Complement System
- Immune Cell Signaling
- Inflammation
Pain Research Product Guide
A collection of over 250 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Alzheimer's Poster
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Asthma Poster
Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.
Epilepsy PosterNew
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Parkinson's Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
